Features of Management of Patients with NAFLD and Sarcopenia

Nowadays non-alcoholic fatty liver disease (NAFLD) and sarcopenia are actually considered as one of the pathological condition with involvement into development of pathology of liver and skeletal muscles. Scientists of different countries found that sarcopenia is associated with insulin resistance and skeletal muscle atrophy as an insulin target organ. Spredly known many cytokines of inflammation with variable affection of skeletal muscle proteins, low level of adiponectin, decreased insulin sensitivity, oxidative stress with activation of catabolism leading to muscle atrophy are involved into complicated pathogenesis of NAFLD. Progressive sarcopenia associated with NAFLD is prognostic factor and can increase the risk of mortality. Sarcopenia, which due to decreased skeletal muscle mass and increased visceral fat, very often provokes development of sarcopenic obesity and NAFLD. Hyperammonemia, abnormal intestinal microbiota, lipid factors also contribute to the development of sarcopenia in patients with NAFLD. Given the common pathogenetic mechanisms indicating a bidirectional relationship between sarcopenia and NAFLD, a multidisciplinary approach to the management of patients with NAFLD and sarcopenia could be the most optimal. Modern strategies are aimed at early diagnosis of NAFLD with sarcopenia, optimizing the lifestyle of these patients, searching for effective drugs, personalizing treatment and prevention of the progression of these diseases and their complications.

1. Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018; 14(2): 99-114. doi: 10.1038/nrendo.2017.173.

2. Targher G, Byrne CD, Lonardo A et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3): 589-600. doi: 10.1016/j.jhep.2016.05.013.

3. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388-402. doi: 10.1016/j.jhep.2015.11.004.

4. Kumar R, Prakash SS, Priyadarshi RN et al. Sarcopenia in Chronic Liver Disease: A Metabolic Perspective. J Clin Transl Hepatol. 2022; 10(6): 1213-1222. doi: 10.14218/JCTH.2022.00239.

5. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci. 2000; 904: 437-48. doi: 10.1111/j.1749-6632.2000.tb06498.x.

6. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412-23. doi: 10.1093/ageing/afq034.

7. Cruz-Jentoft AJ, Bahat G, Bauer J et al; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019; 48(4): 601. doi: 10.1093/ageing/afz046.

8. Cai C, Song X, Chen Y et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol Int. 2020;14(1): 115-126. doi: 10.1007/s12072-019-09964-1.

9. Golabi P, Gerber L, Paik JM et al. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. JHEP Rep. 2020; 2(6): 100171. doi: 10.1016/j.jhepr.2020.100171.

10. Petta S, Ciminnisi S, Di Marco V et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 45(4): 510-518. doi: 10.1111/apt.13889.

11. Hsu CS, Kao JH. Sarcopenia and chronic liver diseases. Expert Rev Gastroenterol Hepatol. 2018;12(12):1229-1244. doi: 10.1080/1747412 4.2018.1534586.

12. Lee YH, Kim SU, Song K et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008- 2011). Hepatology. 2016; 63(3): 776-86. doi: 10.1002/hep.28376.

13. Hong HC, Hwang SY, Choi HY et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014; 59(5): 1772-8. doi: 10.1002/hep.26716.

14. Koo BK, Kim D, Joo SK et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017; 66(1): 123-131. doi: 10.1016/j.jhep.2016.08.019..

15. Qiu J, Tsien C, Thapalaya S et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012; 303(8): E983-93. doi: 10.1152/ajpendo.00183.2012.

16. Lee YH, Jung KS, Kim SU et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015; 63(2): 486-93. doi: 10.1016/j.jhep.2015.02.051.

17. Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023; 29(Suppl): S68-S78. doi: 10.3350/cmh.2022.0358.

18. Lattanzi B, D’Ambrosio D, Merli M. Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration. J Clin Exp Hepatol. 2019; 9(1): 125-130. doi: 10.1016/j.jceh.2018.04.007.

19. Iwaki M, Kobayashi T, Nogami A et al. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease. Nutrients. 2023; 15(4): 891. doi: 10.3390/nu15040891.

20. Kessoku T, Kobayashi T, Imajo K et al. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2021; 12: 770986. doi: 10.3389/fendo.2021.770986.

21. Katsagoni CN, Georgoulis M, Papatheodoridis GV et al. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017; 68: 119-132. doi: 10.1016/j.metabol.2016.12.006.

22. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2): 367- 78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005.

23. Ivashkin V.T., Maevskaya M.V., Zharkova M.S et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 32(4): 104-140. https://doi.org/10.22416/1382-4376-2022-32-4-104-140 [in Russian].

24. Wong VW, Wong GL, Chan RS et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018; 69(6): 1349-1356. doi: 10.1016/j.jhep.2018.08.011.

25. Volkert D, Beck AM, Cederholm T et al. ESPEN practical guideline: Clinical nutrition and hydration in geriatrics. C lin Nutr. 2022; 41(4): 958-989. doi: 10.1016/j.clnu.2022.01.024.

26. Bloom I, Shand C, Cooper C et al. Diet Quality and Sarcopenia in Older Adults: A Systematic Review. Nutrients. 2018; 10(3): 308. doi: 10.3390/nu10030308.

27. Ramadas A, Law HH, Krishnamoorthy R et al. Diet Quality and Measures of Sarcopenia in Developing Economies: A Systematic Review. Nutrients. 2022; 14(4): 868. doi: 10.3390/nu14040868.

28. Cacciatore S, Calvani R, Marzetti E et al. Low Adherence to Mediterranean Diet Is Associated with Probable Sarcopenia in CommunityDwelling Older Adults: Results from the Longevity Check-Up (Lookup) 7+ Project. Nutrients. 2023; 15(4): 1026. doi: 10.3390/nu15041026.

29. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015; 63(3): 705-12. doi: 10.1016/j.jhep.2015.05.006.

30. Athyros VG, Boutari C, Stavropoulos K et al. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Curr Vasc Pharmacol. 2018; 16(3): 246-253. doi: 10.2174/1570161115666170621082910.

31. Sahebkar A, Cicero AFG, Di Giosia P et al. Pathophysiological mechanisms of statin-associated myopathies: possible role of the ubiquitin-proteasome system. J Cachexia Sarcopenia Muscle. 2020; 11(5): 1177-1186. doi: 10.1002/jcsm.12579.

32. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol. 2013; 5(9): 470-8. doi: 10.4254/wjh.v5.i9.470.

33. Crisan E, Patil VK. Neuromuscular Complications of Statin Therapy. Curr Neurol Neurosci Rep. 2020; 20(10): 47. doi: 10.1007/s11910-020-01064-0.

34. Jacobson TA, Cheeley MK, Jones PH et al. The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therap y. J Clin Lipidol. 2019; 13(3): 415-424. doi: 10.1016/j.jacl.2019.04.011.

35. Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012; 15(6): 641-8. doi: 10.1097/MCO.0b013e328357f747.

36. Sanyal AJ, Chalasani N, Kowdley KV et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18): 1675-85. doi: 10.1056/NEJMoa0907929.

37. Balmer ML, Siegrist K, Zimmermann A et al. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009; 29(8): 1184-8. doi: 10.1111/j.1478-3231.2009.02037.x.

38. Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011; 54(5): 1011-9. doi: 10.1016/j.jhep.2010.08.030

39. Gallo P, Flagiello V, Falcomatà A et al. Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis. J Clin Transl Hepatol. 2024; 12(3): 278-286. doi: 10.14218/JCTH.2023.00207.

40. Corona G, Goulis DG, Huhtaniemi I et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology. 2020; 8(5): 970-987. doi: 10.1111/andr.12770.

41. Rolland Y, Dray C, Vellas B et al. Current and investigational medications for the treatment of sarcopenia. Metabolism. 2023; 149: 155597. doi: 10.1016/j.metabol.2023.155597.

42. Kenny AM, Boxer RS, Kleppinger A et al. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc. 2010;58(9):1707-14. doi: 10.1111/j.1532-5415.2010.03019.x.

43. Song Y, Wu Z, Zhao P. The Function of Metformin in Aging-Related Musculoskeletal Disorders. Front Pharmacol. 2022;13:865524. doi: 10.3389/fphar.2022.865524.

44. Kulkarni AS, Gubbi S, Barzilai N. Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab. 2020;32(1):15-30. doi: 10.1016/j.cmet.2020.04.001.

45. Chow LS, Gerszten RE, Taylor JM et al. Exerkines in health, resilience and disease. Nat Rev Endocrinol. 2022;18(5):273-289. doi: 10.1038/s41574-022-00641-2.

46. Prokopidis K, Chambers E, Ni Lochlainn M et al. Mechanisms Linking the Gut-Muscle Axis With Muscle Protein Metabolism and Anabolic Resistance: Implications for Older Adults at Risk of Sarcopenia. Front Physiol. 2021;12:770455. doi: 10.3389/fphys.2021.770455.

47. De Spiegeleer A, Wynendaele E, Descamps A et al. The bacterial quorum sensing peptide iAM373 is a novel inducer of sarcopenia. Clin Transl Med. 2022;12(10):e1053. doi: 10.1002/ctm2.1053.

48. Pillon NJ, Bilan PJ, Fink LN et al. Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. Am J Physiol Endocrinol Metab. 2013;304(5):E453-65. doi: 10.1152/ajpendo.00553.2012.

49. Lancaster GI, Febbraio MA. The immunomodulating role of exercise in metabolic disease. Trends Immunol. 2014;35(6):262-9. doi: 10.1016/j.it.2014.02.008.

50. Kivelä R, Kyröläinen H, Selänne H et al. A single bout of exercise with high mechanical loading induces the expression of Cyr61/CCN1 and CTGF/CCN2 in human skeletal muscle. J Appl Physiol (1985). 2007;103(4):1395-401. doi: 10.1152/japplphysiol.00531.2007.